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YClopidogrel is a prodrug that requires activation by CYP2C19 and other isoenzymes of
the cytochrome P450 system. Carriers of a loss-of-function CYP2C19 allele have lower
levels of the active metabolite, resulting in reduced platelet inhibition and a potentially
higher rate of adverse cardiovascular events. As PPI are competitive inhibitors of
CYP2C19, coadministration with Clopidogrel can further reduce the latter’s antiplatelet
activity.
The COGENT randomised trial which enrolled predominantly white Caucasian
males did not demonstrate any adverse interaction between Clopidogrel and Omep-
razole use. However, this interaction may be signiﬁcant in Asian patients as up to 55%
of Asians carry a loss-of-function CYP2C19 allele as compared to 30% of Caucasians.
We hypothesize that Asian patients taking both Clopidogrel and the PPI Omeprazole
are at higher risk of adverse cardiovascular events post-PCI.
Methods: This retrospective cohort study in a 1300-bed tertiary hospital in Singapore
included all patients from 1st January to 31st December 2011 who had PCI and
received either Omeprazole or a H2RA, together with 12 months of Aspirin and
Clopidogrel. Prescription and outcome data were retrieved from electronic medical
records. The primary outcome was the incidence of cardiovascular complications
within 12 months of the initial PCI. Cardiovascular complication is deﬁned as car-
diovascular death, non-fatal myocardial infarction, need for urgent target vessel
revascularisation and ischemic stroke.
Results: We identiﬁed 933 patients, of which 614 patients met the criteria for in-
clusion. The primary outcome occurred in 27 of 296 patients (9.1%) from the
Omeprazole group and 13 of 318 patients (4.1%) from the H2RA group (p ¼ 0.014).
The difference remained statistically signiﬁcant after adjustment for baseline differ-
ences in cardiovascular risk factors in both groups (p ¼ 0.042).
Conclusions: Using Omeprazole rather than a H2RA was associated with a signif-
icantly greater incidence of cardiovascular complications in Asian patients on Clopi-
dogrel after PCI. Larger studies are required to further evaluate this observation.
CRT-134
Metformin Does Not Adversely Impact Outcome Following Percutaneous Coronary
Intervention in Patients with Diabetes Mellitus
Michael J. Lipinski, Lakshmana Pendyala, Rebecca Torguson, Fang Chen,
Lowell F. Satler, William O. Suddath, Augusto D. Pichard, Ron Waksman
MedStar Heart Institute, Washington, VA
Background: The use of metformin in patients with non-insulin-dependent diabetes
mellitus (NIDDM) has been associated with improved cardiovascular outcomes. How-
ever, recent studies raise concern that use of metformin may inhibit endothelialization
following limus-eluting stent (LES) placement and increase the risk of stent thrombosis.
Therefore, we set out to study the impact of metformin on stent thrombosis and major
adverse cardiovascular events in patients that received drug-eluting stents (DES).
Methods: We evaluated consecutive patient with NIDDM discharged on oral anti-
hyperglycemic agents that underwent DES placement at our institution from 2003
through 2012. We assessed stent thrombosis, major adverse cardiovascular events
(MACE), target lesion revascularization, myocardial infarction, and all-cause mortality
at one year and analyzed the impact of metformin use and stent type on these outcomes.
Results: We included 1,201 patients with a mean age of 66  10 years, 64.1% were
male, 63.5% had ACS, 74.8% received LES, 25.2% received paclitaxel-eluting stents
(PES), and 55% were taking Metformin. There was no difference in stent thrombosis,
regardless of stent type or metformin use. Whether or not patients received LES or PES
did not signiﬁcantly impact MACE (Figure 1A) or all-cause mortality (Figure 1B).
Patients takingmetformin had a signiﬁcant reduction inMACE (p¼0.002) and all-cause
mortality (p¼0.002) compared with patients not taking metformin (Figure 1C and
Figure 1D, respectively). However, multivariate analysis demonstrated that stent type and
metformin use were not signiﬁcantly associated with MACE or all-cause mortality.
Conclusion: In patients with NIDDM, the use of metformin following placement of
DES did not increase the risk of stent thrombosis and MACE, regardless of the type
of stent placed.Chronic Total Occlusion
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Rationale of the Decision-Making of Treatment in Chronic Total Occlusion Lesions in a
University Hospital
Luis R. Alvarez-Contreras, Victoria Martin-Yuste, Salvatore Brugaletta,
Yajaziel Azpeitia-Hernandez, Alejandro Santos, Manel Sabate
Hospital Clinic de Barcelona, Barcelona, Spain
Background: The presence of a chronic total occlusion (CTO) in up to 30% of
routine angiograms emphasizes the importance to select an optimal treatment strategy
effectiveness of its treatment and its implication in future clinical events.
Objective:We assessed the rationale for decision-making in treatment of CTO at our
institution.
Methods: From June 2010 to December 2012 we evaluated all consecutive patients in
our catheterization laboratory in which at least one CTO was diagnosed. Data were
prospectively collected on treatment decisions (medical vs. surgery vs. percutaneous
coronary intervention <PCI>), PCI indications and subsequent cardiac events
through time.
Results: 711 patients with at least one CTO in the basal coronary angiogram were
included. Two groups were made according to programmed to PCI (PPCI)¼189
patients and non-programed to PCI (NPPCI)¼522 patients. There was a statistical
difference among basal characteristics in patients PPCI vs. NPPCI with less acute
myocardial infarction (AMI) 16(13,6%) vs. 81(15,5%) p¼0.016; less involvement of
3-vessel disease 56(29,6%) vs. 224 (42,9%) p¼0.002; and less presence of coronary
left-main disease 12 (6,4%) vs. 72 (13,8%) p¼0.007. There was also a difference
between age (62,610.4 years vs. 68,310.7 years; p¼<0.0001); ejection fraction
(EF) (47,113,8% vs. 44,913,9;p¼0.017%) and creatinine clearance (70,8 28,6
ml/min vs. 62 23,1, ml/min; p¼<0.001). The multivariate analysis demonstrated
that the following variables in predicting no PCI as ﬁrst step approach in CTO
lesions: AMI, number of diseased vessels, left main lesion and age. There was a
trend to be treated by PCI as ﬁrst step approach in patients with positive ischemia
by a stress test.
Conclusion: In a large all comer CTO lesion population, in a University hospital; the
ﬁrst step approach of revascularization is dictated by clinical factors as age, comorbidity
(EF and creatinine clearance), AMI; anatomical factors such as left-main disease and
3-vessel disease. On the other hand, at our institution the choice of PCI as ﬁrst step
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ischemia test.
CRT-136*
Retrograde Recanalization of Chronic Total Occlusions in Europe: Procedural and
In-Hospital Outcomes from the Multicenter Ercto Registry
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Objective: The aim of this study was to describe the ﬁve-year European experience of
retrograde percutaneous coronary interventions (PCI) revascularization for complex
chronic total occlusions (CTOs) of coronary arteries.
Background: Retrograde approach increases the success rate of percutaneous recan-
alization of complex CTOs of coronary arteries.
Methods: Demographic data, procedural outcomes and in-hospital clinical events
were collected on 1582 consecutive lesions of 1395 patients enrolled between January
2008 and December 2012 having retrograde CTO PCI at 44 European medical
centers by 45 experienced interventionalist operators. A revision of J-CTO score
proposed for antegrade lesions was used to better describe success according to lesion
difﬁculty.
Results: Patients mean age was 62.010.4 years, 88.5% were men, 17.6% had prior
coronary artery bypass surgery. The CTO target vessel was the right coronary artery
(70.4%), circumﬂex (7.8%), left anterior descending artery (20.3%), and left main
artery or by-pass graft (1.5%). The retrograde approach was used after prior failed
attempt in 43.5% of cases. During the procedure the retrograde approach was used as
ﬁrst line strategy in 76.2% of cases, while immediately after antegrade failed approach
in 23.8% of cases. Retrograde collateral vessels were septal (62.7%), epicardial (13.4%),
by-pass graft (3.9%) or missing information (20.0%). Technical success was 75.3%
(n¼1.191). The mean contrast volume and ﬂuoroscopy time were 396.3171.3 ml
and 69.834.1 mins, respectively. A major complication occurred in 16 patients
(1.0%). In multivariable analysis, age of the patient (per 10-year increase), lower
operator volume (<50, 50-100, >100), increased J-CTO score were signiﬁcantly
associated with increased technical failure, (p¼0.01, p<0.001, p<0.001), respectively.
Conclusion: In Europe among selected centers dedicated to CTO revascularization,
retrograde approach was performed over a 5-year period in 16.5% of these patients.
The number of retrograde procedures were exponentially increasing during the last 2
years and were associated with high success and low major complications rates.
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Myocardial Perfusion in Patients with Total Occlusion of a Single Coronary Artery with
and without Collateral Circulation
Maged S. El-Gantiry
Dar Al Fouad Hospital, 6th of October - Cairo, Egypt
Background: Previous studies that investigated the effects of coronary collateral cir-
culation on myocardial perfusion were compromised by inclusion of patients with
multivessel coronary artery disease, incomplete occlusion, prior myocardial infarction,
or a combination of these.
Aim of work: In this study we will investigate the relationship between angiographic
collateral circulation and myocardial perfusion in patients with total occlusion of a*Indicates iMPACT Trial Accepted for Oral Presentationsingle coronary artery, in the absence of myocardial infarction or signiﬁcant stenosis in
the other coronary arteries supplying the same myocardial territory.
Methods and Results: Forty patients underwent stress myocardial single photon
emission computed tomography within 90 days of angiography. Collateral circulation
was present in 24 patients (group A) and absent in 16 patients (group B). Reversible
perfusion defects were present in 22(91.7%) patients in group A and in 12(75%) in
group B, comparison between both groups came back statistically insigniﬁcant (p-value
¼ NS). Group A included 4(18.2%) patients with a small size defect (<5%), 9(40.9%)
patients with a moderate perfusion defect (5-10%) and 9(40.9%) patients with a large
perfusion defect (>10%); while group B had 2(16.6%) patients with small perfusion
defect, 5(41.6%) patients with a moderate perfusion defect and also 5(41.6%) patients
with a large perfusion defect, comparison between both groups came back statistically
insigniﬁcant (p-value ¼ NS). The mean exercise time for patients in group A was 6.9
0.92 minutes and their mean achieved peak METs was 7.350.35 METs. On the
other hand; the mean exercise time for patients in group B was 6.9 0.83 minutes and
their mean peak METs was 7.230.25 METs. Comparison between both groups also
appeared to be statistically insigniﬁcant (p-value ¼ NS).
Conclusion: In patients with a single-vessel total coronary occlusion and without
myocardial infarction, stress-induced myocardial ischemia is almost always present,
irrespective of presence or absence of angiographic collaterals. These data suggest that
coronary collaterals do not appear to protect against stress-induced perfusion defects.
Nevertheless collaterals in our study did not have any positive impact on the functional
capacity of patients, predicted by the analysis of exercise duration and achieved peak
METs.
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Background: There are limited data comparing angiographic and clinical outcomes of
re-stenotic stented chronic total occlusive (CTO) lesion successfully revascularized
with drug-eluting stents (DESs) with those of de novo CTO lesion.
Methods: The study population consisted of consecutive 269 CTO patients (pts) who
successfully treated with DESs between January 2004 and June 2010. A total 249 pts
with de novo CTO lesion and 20 pts with re-stenotic stented CTO lesion were
included for analysis. The 6-to-9 month angiographic and 2-year clinical outcomes
were compared between the 2 groups.
Results: The baseline clinical characteristics were similar between the two groups
except prior myocardial infarction, LDL-cholesterol level, number of total implanted
stent and use of cilostazol. Angiographic outcomes at 6-to-9 months were similar
between the two groups. At 2-year follow-up, the incidence of major clinical outcomes
including all death, any myocardial infarction, any revascularization, target lesion and
vessel revascularization (TLR and TVR) and major adverse cardiac events (MACEs)
were similar between the two groups (Table). Further, even after adjustment of
baseline differences with multivariate analysis adjusted by age, gender, dyslipidemia,
LVEF, Lefevre classiﬁcation, all the major clinical outcomes were similar between the
two groups.
Conclusion: In our study, there were no difference in 6-to-9 month angiographic and
2-year clinical outcomes between pts with stented and de novo CTO lesions once the
CTO pts were successfully treated with DESs.
